viewe-Therapeutics PLC

Change of focus leads to departure of development director at e-Therapeutics

Pharma veteran Steve Self is moving on following the company's decision to focus on its discovery platform

Lab technician
ETX plans to focus more on its discovery platform

Steve Self is to stand down as development director at e-Therapeutics PLC (LON:ETX) and leave the company at the end of the month.

The drugs discovery and developer noted in its stock market statement that it had indicated back in March, at the time of its full-year results, that it intended to focus more on the discovery side of things, and the implication is that this has been the reason behind the parting of the ways with Self.

"Steve joined e-Therapeutics in December 2010 following a distinguished career at The Wellcome Foundation, Boots Healthcare and as R&D Director of Merck's Generic Global business. We thank him for his significant contribution to our activities and wish him continuing success in his new endeavours," said Iain Ross, executive chairman of e-Therapeutics.

The company is clearly going through a transitional phase as the two most advanced of its discovery compounds approach the lead candidate selection process, ahead of entering pre-clinical development in the coming months.

Professor Malcolm Young, who founded the company, stood down as chief executive in July, with chairman Ross assuming executive duties until a replacement can be found.

Quick facts: e-Therapeutics PLC

Price: 13.7 GBX

Market: AIM
Market Cap: £57.41 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics PLC named herein, including the promotion by the Company of e-Therapeutics PLC in any Content on the Site, the Company receives...


2 min read